ResMed IncNYSE: RMD
Health Care · Health Care Equipment
$205.55
-3.86%
Vol: 3.8M
Research Digest
Friday, May 1, 2026
ResMed surpasses Q3 earnings at $2.86 EPS; CFO transition underway
ResMed delivered strong Q3 FY2026 results with EPS of $2.86 beating estimates of $2.79 and revenue of $1.43B surpassing consensus. The company posted 11% revenue growth and 290 basis points of gross margin expansion. CFO Brett Sandercock is retiring effective May 4 with Aaron Bloomer, formerly of Exact Sciences, appointed as successor. Analysts rate the stock as 'Buy' with a 12-month target of $292.56, suggesting 37% upside from current levels.
Previous Market Intelligence
13 daysApr 30ResMed earnings release scheduled for April 30 amid analyst price target cutsNeutral▶
ResMed announces Q1 2026 earnings today with expectations for EPS of $0.41 and $2.06B revenue. Evercore ISI cut price target to $255 from $300 on April 13. KeyBanc lowered target to $290 from $302 on April 27. Despite recent cuts, consensus rating is "Buy" with average price target of $292.56 (36.93% upside). Net income growth accelerated 37.2% YoY, outpacing 9.8% revenue growth. Vanguard lowered position by 0.8% in Q4.
Apr 29ResMed Q2 EPS $2.81 beats; revenue growth 10% YoY on strong sleep apnea demandPositive▶
ResMed reported Q2 fiscal 2026 earnings with EPS of $2.81 beating consensus of $2.73 and revenue of $1.4B meeting expectations. Stock rose 1.56% on positive investor reaction to strong sleep apnea device demand. Recent analyst adjustments: RBC Capital raised target to $314 from $311, KeyBanc increased to $302 from $299 maintaining Overweight. Company hit 52-week low at $218.27 recently. Vanguard lowered position by 0.8% while Vest Financial grew holdings 123.8% in Q4. Buy consensus from 10 analysts with $292.56 target (+36.9% upside) reflecting confidence in organic growth trajectory.
Apr 16ResMed Q3 fiscal 2026 earnings expected April 30 with strong sleep apnea device demand offsetting recent stock headwinds.Positive▶
ResMed has experienced positive momentum with strong demand for sleep apnea devices, with stock rising 1.56% recently. The company is set to report Q3 fiscal 2026 earnings on April 30, 2026, amid recent price declines. Analysts expect EPS of $2.77, up 16.9% year-over-year, suggesting potential undervaluation. Citi lowered price target to $340 from $345 on April 9. Stock price: $220.03, down -0.27% in past 24 hours.
Apr 15ResMed set to report Q3 fiscal 2026 earnings on April 30 with EPS expected at $2.77, up 16.9% YoY; analysts maintain Buy.Positive▶
ResMed announced it will report Q3 fiscal 2026 earnings on April 30, 2026. Q2 adjusted earnings of $2.81 beat consensus of $2.72. CEO Michael Farrell sold 4,991 shares on April 7. Analysts expect Q3 EPS of $2.77 (up 16.9% YoY) and maintain Buy with $293.7 target.
Apr 14Citigroup downgrades ResMed price target to $340 amid Q3 earnings anticipation.Mixed▶
Citigroup analyst maintained Buy rating but cut ResMed price target from $345 to $340 on April 9. ResMed is scheduled to report Q3 fiscal 2026 earnings on April 30 after market close, with analysts expecting EPS of $2.77, up 16.9% year-over-year.
Apr 13Q3 fiscal 2026 earnings due April 30; insider sales in early April; Citigroup maintained Buy but cut target from $345 to $340.Neutral▶
ResMed scheduled Q3 fiscal 2026 earnings release for April 30. Beat consensus in Q2 with adjusted EPS of $2.81 vs $2.72. Recent insider sales: Peter Farrell sold 2,000 shares April 1; CFO sold 1,000 shares April 1; CEO sold 4,991 shares April 7. Citigroup maintained Buy but lowered target from $345 to $340. Consensus Buy from 10 analysts with $293.70 target.
Apr 10CEO Farrell sells $1.12M in stock; Q3 earnings scheduled for April 30 with analyst rating maintained but price target lowered by Citigroup.Mixed▶
ResMed CEO Michael Farrell sold 4,991 shares on April 7 for $1.12M under a Rule 10b5-1 trading plan. Citigroup analyst Laura Sutcliffe maintained a Buy rating on April 9 but revised the price target from $345 to $340. The company is scheduled to report Q3 fiscal 2026 earnings on April 30 after market close.
Apr 9ResMed Q3 FY2026 earnings April 30; Q2 EPS $2.81 beat consensusPositive▶
ResMed Inc. reports Q3 fiscal 2026 earnings on April 30, 2026 after NYSE close. Q2 FY2026 adjusted EPS $2.81, beat consensus $2.72. Q3 EPS expected $2.77, up 16.9% YoY. Stock rose 1.56% on strong sleep apnea device demand, outpacing market. 10 analysts rate Buy with $293.7 target (+31.06%). Concerns include insider selling (no insider purchases past year) and recent declines (-10.6% 30-day, -7.7% YTD). Aberdeen Group reduced stake 13.6% in Q4. Company manufactures medical devices and cloud software for respiratory and residential care solutions.
Apr 8ResMed beats Q2 earnings; strong CPAP demand; Q3 earnings April 30Positive▶
ResMed reported Q2 fiscal 2026 adjusted earnings of $2.81, beating $2.72 consensus. Stock rose 1.56% on strong sleep apnea device demand, outpacing market 0.63% gain. Tested smart CPAP pressure tool in new sleep apnea trial (Feb 2026). Q3 FY2026 earnings due April 30, 2026; analysts expect $2.77 EPS (up 16.9% YoY) with potential undervaluation. 10 analysts rate "Buy" with $293.7 average 12-month target (up 31.06% from current). ResMed operates Sleep & Breathing Health and Residential Care Software segments.
Apr 7ResMed CFO sold 1,000 shares; Q3 FY2026 earnings April 30.Positive▶
ResMed CFO Sandercock sold 1,000 shares at $224.31 April 2. Q2 FY26 adjusted EPS beat at $2.81 vs $2.72. Strong sleep apnea demand drove FY25 +9.84% to $5.15B. Q3 FY26 April 30. Stock $293.70 target (+31%).
Apr 6ResMed CFO Insider Sale; Q3 Earnings Expected April 30Positive▶
ResMed CFO Brett Sandercock sold 1,000 shares at $224.31 in open-market transaction under Rule 10b5-1 plan. The company is scheduled to report Q3 fiscal 2026 earnings on April 30, 2026. Analysts expect EPS of $2.77, up 16.9% year-over-year, suggesting potential undervaluation. Stock closed at $224.48, up 2.02% on the day. After-hours trading showed slight decline to $223.86.
Apr 3ResMed announced Q3 FY2026 earnings release date of April 30; director Peter Farrell sold $450K in stock.Positive▶
ResMed announced Q3 FY2026 earnings release on April 30 after NYSE close. Director Peter C. Farrell sold 2,000 shares at $225.00 per share ($450K total) on April 1. Stock performed positively, rising 1.56% on strong demand for sleep apnea devices. Trading at $224.09 with day range $219.01-$226.30. Strong Q2 FY2026 results previously reported $1.423B revenue.
Apr 2ResMed director sells $450K in stock; Q3 FY2026 earnings scheduled April 30; RBC Capital raised PT to $314 with Outperform rating.Mixed▶
ResMed announced Q3 fiscal 2026 earnings release for April 30, 2026 after market close, with webcast at 4:30 p.m. ET. Insider selling activity detected: director Farrell sold $450,000 in stock at $225/share. Stock trading at $224.09, recovering after hours at $225.88 (+0.80%). RBC Capital raised price target to $314 with Outperform rating; KeyBanc raised to $302. Analyst consensus Buy (10 analysts) with 12-month target $293.70 (33.59% upside).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| RMDRESMED | $205.55 | -3.86% | -4.9% | 17.6x | 0.93 | $31.1B |
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.